S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
Log in
LON:AZN

AstraZeneca PLC (AZN.L) Share Forecast, Price & News

GBX 7,828.53
-123.47 (-1.55 %)
(As of 01/27/2021 01:21 PM ET)
Add
Compare
Today's Range
7,809
Now: GBX 7,828.53
7,998
50-Day Range
7,223
MA: GBX 7,569.33
8,160
52-Week Range
5,871
Now: GBX 7,828.53
£101.20
Volume1.08 million shs
Average Volume2.36 million shs
Market Capitalization£102.76 billion
P/E Ratio41.20
Dividend Yield2.82%
BetaN/A
AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR/Komboglyze, Onglyza, Qtern, Symlin, Xigduo/Xigduo XR for metabolic diseases. The company's marketed products also comprise Accolate, Bevespi Aerosphere, Bricanyl Respules, Bricanyl Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Tudorza/Eklira, Fasenra, Oxis Turbuhaler, Pulmicort Turbuhaler/Pulmicort Flexhaler, Pulmicort Respules, Symbicort pMDI, and Symbicort Turbuhaler for respiratory diseases; Fluenz Tetra/FluMist Quadrivalen and Synagis for infection diseases; Movantik/Moventig, Seroquel IR/Seroquel XR, and Vimovo for neuroscience diseases; and Losec/Prilosec and Nexium for gastrointestinal diseases. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Arcus Biosciences, Inc. to evaluate domvanalimab (AB154), an investigational anti-TIGIT antibody in combination with Imfinzi (durvalumab); Fusion Pharmaceuticals Inc. to develop and commercialize next-generation alpha-emitting radiopharmaceuticals and combination therapies for the treatment of cancer; and Recombinetics Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was founded in 1992 and is headquartered in Cambridge, the United Kingdom.
AstraZeneca PLC (AZN.L) logo

MarketRank

Overall MarketRank

1.42 out of 5 stars

Analyst Opinion: 2.2Community Rank: 2.4Dividend Strength: 0.8Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-73045000
Employees70,600
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales£25.87 billion
Cash FlowGBX 648.07 per share
Book ValueGBX 929.50 per share

Profitability

Miscellaneous

Outstanding Shares1,312,669,952
Market Cap£102.76 billion
Next Earnings Date2/11/2021 (Estimated)
OptionableOptionable
GBX 7,828.53
-123.47 (-1.55 %)
(As of 01/27/2021 01:21 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AZN News and Ratings via Email

Sign-up to receive the latest news and ratings for AZN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AstraZeneca PLC (AZN.L) (LON:AZN) Frequently Asked Questions

How has AstraZeneca PLC (AZN.L)'s stock been impacted by Coronavirus (COVID-19)?

AstraZeneca PLC (AZN.L)'s stock was trading at GBX 6,955 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AZN stock has increased by 13.2% and is now trading at GBX 7,875.
View which stocks have been most impacted by COVID-19
.

Is AstraZeneca PLC (AZN.L) a buy right now?

20 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca PLC (AZN.L) in the last twelve months. There are currently 5 sell ratings, 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AstraZeneca PLC (AZN.L) stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AZN, but not buy additional shares or sell existing shares.
View analyst ratings for AstraZeneca PLC (AZN.L)
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than AstraZeneca PLC (AZN.L)?

Wall Street analysts have given AstraZeneca PLC (AZN.L) a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but AstraZeneca PLC (AZN.L) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is AstraZeneca PLC (AZN.L)'s next earnings date?

AstraZeneca PLC (AZN.L) is scheduled to release its next quarterly earnings announcement on Thursday, February 11th 2021.
View our earnings forecast for AstraZeneca PLC (AZN.L)
.

How often does AstraZeneca PLC (AZN.L) pay dividends? What is the dividend yield for AstraZeneca PLC (AZN.L)?

AstraZeneca PLC (AZN.L) announced a dividend on Thursday, July 30th. Shareholders of record on Thursday, August 13th will be paid a dividend of GBX 69.60 per share on Monday, September 14th. This represents a dividend yield of 0.8%. The ex-dividend date of this dividend is Thursday, August 13th. The official announcement can be seen at this link.
View AstraZeneca PLC (AZN.L)'s dividend history
.

Is AstraZeneca PLC (AZN.L) a good dividend stock?

AstraZeneca PLC (AZN.L) pays an annual dividend of GBX 216 per share and currently has a dividend yield of 2.82%. The dividend payout ratio of AstraZeneca PLC (AZN.L) is 113.68%. Payout ratios above 75% are not desirable because they may not be sustainable.
View AstraZeneca PLC (AZN.L)'s dividend history.

What price target have analysts set for AZN?

20 brokers have issued 1-year price objectives for AstraZeneca PLC (AZN.L)'s shares. Their forecasts range from GBX 6,575 to £105. On average, they expect AstraZeneca PLC (AZN.L)'s share price to reach GBX 8,596.76 in the next twelve months. This suggests a possible upside of 9.2% from the stock's current price.
View analysts' price targets for AstraZeneca PLC (AZN.L)
or view Wall Street analyst' top-rated stocks.

Who are some of AstraZeneca PLC (AZN.L)'s key competitors?

What other stocks do shareholders of AstraZeneca PLC (AZN.L) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca PLC (AZN.L) investors own include GlaxoSmithKline plc (GSK.L) (GSK), NVIDIA (NVDA), Gilead Sciences (GILD), Intel (INTC), Vodafone Group Plc (VOD.L) (VOD), Advanced Micro Devices (AMD), Alibaba Group (BABA), Pfizer (PFE), QUALCOMM (QCOM) and The Hain Celestial Group (HAIN).

Who are AstraZeneca PLC (AZN.L)'s key executives?

AstraZeneca PLC (AZN.L)'s management team includes the following people:
  • Mr. Pascal Soriot D.V.M., M.B.A., CEO & Exec. Director (Age 62, Pay $3.84M)
  • Mr. Marc Dunoyer, CFO & Exec. Director (Age 69, Pay $2.02M)
  • Ms. Pam P. Cheng, Exec. Vice-Pres of Operations & Information Technology (Age 50)
  • Thomas Kudsk Larsen, Head of Investor Relations
  • Mr. Jefrey Pott, Exec. VP of HR & Gen. Counsel
  • Ms. Katarina Ageborg, Exec. VP of Sustainability & Chief Compliance Officer
  • Dr. Menelas Pangalos, Exec. Vice-Pres of BioPharmaceuticals R&D
  • Dr. Ruud Dobber, Exec. Vice-Pres of BioPharmaceuticals Bus. Unit
  • Dr. Susan Mary Galbraith, Sr. VP and Head of Research, Early Devel. & Oncology R&D (Age 55)
  • Dr. David B. Goldstein Ph.D., Chief Adviser

What is AstraZeneca PLC (AZN.L)'s stock symbol?

AstraZeneca PLC (AZN.L) trades on the London Stock Exchange (LON) under the ticker symbol "AZN."

How do I buy shares of AstraZeneca PLC (AZN.L)?

Shares of AZN and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is AstraZeneca PLC (AZN.L)'s stock price today?

One share of AZN stock can currently be purchased for approximately GBX 7,875.

How big of a company is AstraZeneca PLC (AZN.L)?

AstraZeneca PLC (AZN.L) has a market capitalization of £103.37 billion and generates £25.87 billion in revenue each year. AstraZeneca PLC (AZN.L) employs 70,600 workers across the globe.

What is AstraZeneca PLC (AZN.L)'s official website?

The official website for AstraZeneca PLC (AZN.L) is www.astrazeneca.com.

How can I contact AstraZeneca PLC (AZN.L)?

AstraZeneca PLC (AZN.L)'s mailing address is 1 Francis Crick Avenue Cambridge Biomedical Campus, CAMBRIDGE, CB2 0AA, United Kingdom. The biopharmaceutical company can be reached via phone at +44-20-73045000.

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.